Millennium Management’s Aldeyra Therapeutics ALDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.68M | Buy |
995,243
+951,184
| +2,159% | +$4.17M | ﹤0.01% | 4022 |
|
|
2025
Q4 | $228K | Sell |
44,059
-105,306
| -71% | -$541K | ﹤0.01% | 5408 |
|
|
2025
Q3 | $780K | Buy |
149,365
+129,759
| +662% | +$677K | ﹤0.01% | 4809 |
|
|
2025
Q2 | $75.1K | Sell |
19,606
-115,549
| -85% | -$299K | ﹤0.01% | 5553 |
|
|
2025
Q1 | $777K | Sell |
135,155
-26,771
| -17% | -$158K | ﹤0.01% | 4537 |
|
|
2024
Q4 | $808K | Buy |
+161,926
| New | +$831K | ﹤0.01% | 4372 |
|
|
2024
Q3 | – | Sell |
-43,825
| Closed | -$145K | – | 6052 |
|
|
2024
Q2 | $145K | Sell |
43,825
-344,880
| -89% | -$1.35M | ﹤0.01% | 5239 |
|
|
2024
Q1 | $1.27M | Sell |
388,705
-51,683
| -12% | -$170K | ﹤0.01% | 4100 |
|
|
2023
Q4 | $1.55M | Sell |
440,388
-141,790
| -24% | -$438K | ﹤0.01% | 3814 |
|
|
2023
Q3 | $3.89M | Buy |
582,178
+86,603
| +17% | +$643K | ﹤0.01% | 2949 |
|
|
2023
Q2 | $4.16M | Sell |
495,575
-622,856
| -56% | -$6.14M | ﹤0.01% | 2831 |
|
|
2023
Q1 | $11.1M | Buy |
1,118,431
+268,343
| +32% | +$1.9M | 0.01% | 1850 |
|
|
2022
Q4 | $5.92M | Buy |
850,088
+203,694
| +32% | +$1.16M | ﹤0.01% | 2667 |
|
|
2022
Q3 | $3.45M | Sell |
646,394
-590,358
| -48% | -$3.54M | ﹤0.01% | 3238 |
|
|
2022
Q2 | $4.93M | Buy |
1,236,752
+732,290
| +145% | +$2.52M | ﹤0.01% | 2824 |
|
|
2022
Q1 | $2.24M | Sell |
504,462
-1,154,473
| -70% | -$4.6M | ﹤0.01% | 3770 |
|
|
2021
Q4 | $6.64M | Buy |
1,658,935
+1,255,992
| +312% | +$9.58M | ﹤0.01% | 2611 |
|
|
2021
Q3 | $3.54M | Sell |
402,943
-7,605
| -2% | -$69.8K | ﹤0.01% | 3281 |
|
|
2021
Q2 | $4.65M | Sell |
410,548
-133,275
| -25% | -$1.6M | ﹤0.01% | 2856 |
|
|
2021
Q1 | $6.46M | Sell |
543,823
-15,232
| -3% | -$175K | ﹤0.01% | 2308 |
|
|
2020
Q4 | $3.83M | Buy |
559,055
+224,441
| +67% | +$1.58M | ﹤0.01% | 2706 |
|
|
2020
Q3 | $2.48K | Sell |
334,614
-233,283
| -41% | -$1.51M | ﹤0.01% | 2429 |
|
|
2020
Q2 | $2.37M | Sell |
567,897
-251,930
| -31% | -$920K | ﹤0.01% | 2400 |
|
|
2020
Q1 | $2.02M | Buy |
819,827
+21,805
| +3% | +$98.1K | ﹤0.01% | 2009 |
|
|
2019
Q4 | $4.64M | Buy |
798,022
+264,390
| +50% | +$1.53M | 0.01% | 1998 |
|
|
2019
Q3 | $2.81M | Buy |
533,632
+293,278
| +122% | +$1.58M | ﹤0.01% | 2219 |
|
|
2019
Q2 | $1.44M | Sell |
240,354
-146,079
| -38% | -$1.1M | ﹤0.01% | 2600 |
|
|
2019
Q1 | $3.49M | Sell |
386,433
-271,543
| -41% | -$2.31M | 0.01% | 2009 |
|
|
2018
Q4 | $5.46M | Sell |
657,976
-289,249
| -31% | -$2.96M | 0.01% | 1530 |
|
|
2018
Q3 | $13.1M | Buy |
947,225
+222,273
| +31% | +$1.8M | 0.02% | 1109 |
|
|
2018
Q2 | $5.76M | Sell |
724,952
-28,191
| -4% | -$225K | 0.01% | 1716 |
|
|
2018
Q1 | $5.65M | Buy |
753,143
+37,464
| +5% | +$284K | 0.01% | 1722 |
|
|
2017
Q4 | $4.87M | Buy |
715,679
+170,594
| +31% | +$1.12M | 0.01% | 1748 |
|
|
2017
Q3 | $3.92M | Buy |
545,085
+444,585
| +442% | +$2.32M | 0.01% | 1799 |
|
|
2017
Q2 | $467K | Sell |
100,500
-2,885
| -3% | -$13.3K | ﹤0.01% | 2832 |
|
|
2017
Q1 | $517K | Buy |
103,385
+3,385
| +3% | +$17.4K | ﹤0.01% | 2799 |
|
|
2016
Q4 | $535K | Sell |
100,000
-3
| -0% | -$18 | ﹤0.01% | 2647 |
|
|
2016
Q3 | $782K | Sell |
100,003
-30,497
| -23% | -$186K | ﹤0.01% | 2397 |
|
|
2016
Q2 | $743K | Buy |
130,500
+30,455
| +30% | +$170K | ﹤0.01% | 2300 |
|
|
2016
Q1 | $419K | Sell |
100,045
-9,979
| -9% | -$48K | ﹤0.01% | 2608 |
|
|
2015
Q4 | $746K | Sell |
110,024
-6,076
| -5% | -$40.8K | ﹤0.01% | 2445 |
|
|
2015
Q3 | $677K | Sell |
116,100
-2,900
| -2% | -$22.6K | ﹤0.01% | 2493 |
|
|
2015
Q2 | $923K | Buy |
+119,000
| New | +$1.03M | ﹤0.01% | 2328 |
|
Other funds holding ALDX
KCM
VCM
KCM
6CM
Millennium Management's ALDX Position: Q1 2026 in Review
Millennium Management increased its Aldeyra Therapeutics (ALDX) stake by 2,159% in Q1 2026, buying an estimated $4.17M and bringing the position to 995,243 shares worth $1.68M. The position accounts for ﹤0.01% of the portfolio, ranked #4022.
Millennium Management first reported a position in ALDX in Q2 2015 and has held it in 43 quarters since. The position peaked at $13.1M in Q3 2018. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.
- Millennium Management held 995,243 shares of Aldeyra Therapeutics worth $1.68M as of Q1 2026.
- Millennium Management bought 951,184 Aldeyra Therapeutics shares in Q1 2026, an estimated $4.17M.
- Aldeyra Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #4022 holding.
- Millennium Management first reported a position in Aldeyra Therapeutics in Q2 2015 and has held it in 43 quarters since.
- Millennium Management's Aldeyra Therapeutics position peaked at $13.1M in Q3 2018.
- 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.